Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
 |
New Vision (Kampala) - October 21, 2007
Fred Ouma
Speaking at the launch of the INTERACT programme at the Infectious Diseases Institute in Mulago last week, Lange told health specialists that the funding tends to reward duplication and small incremental steps, rather than the boldness the HIV epidemic calls for.
He said several patients were still not accessing HIV treatment due to the growing epidemic, while the few enrolled on treatment depended on cheap fixed doses for first-line therapy, resulting in high early mortality rates.
The problem, he added, was compounded by limited availability of second-line options as well as inadequate monitoring capacity.
"In 2006, there were 4.3 million new infections worldwide. We may never be able to provide universal access to anti-retroviral therapy if we are unable to bring down the numbers of new infections significantly," Lange said.
Out of 240,000 Ugandans in need of anti-retroviral treatment, only 105,000 are receiving the drugs, according to Dr. Kihumuro Apuuli, the director of the Uganda AIDS Commission.
According to the national HIV/AIDS sero-survey, new infections were estimated to have increased from 132,000 people in 2005 to 136,000 in 2006.
Gender inequality has been noted as an important factor in HIV transmission and experts recommended that a more programmatic approach towards gender equality be adopted when implementing national plans.
Prof. Keith McAdam of the Infectious Disease Institute said national plans on HIV/AIDS, tuberculosis and malaria require the full involvement of non-health sectors and local governments.
The INTERACT programme, worth 5m Euros, is a partnership between Rwandan, Ugandan and European scientists who reflect on the interaction of malaria, TB and HIV.
071021
NV071012
Copyright © 2007 - The New Vision. All articles are republished on AEGIS by permission. Material may not be redistributed, posted to any other location, published or used for broadcast without written authorization from Managing Director/Editor-in-chief, The New Vision, P.O. Box 9815, Kampala - Uganda, Tel/fax: 256-41-235221, E-mail: wpike@newvision.co.ug.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .